Protein– tag –
-
Soufflé Therapeutics Initiates Phase I/II Clinical Trial for Muscle-Targeted siRNA Conjugate SFL-0821 in FSHD
allsci.com USA Overview Soufflé Therapeutics has commenced a Phase I/II clinical trial for SFL-0821, a novel antibody-siRNA conjugate designed for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). SFL-0821 specifically targets... -
Bepirovirsen Achieves 20% Functional Cure Rate in Chronic Hepatitis B, Approved in Japan, Filed in China, FDA PDUFA October 2026
OligoTherapeutics.org Japan Overview The antisense oligonucleotide (ASO) bepirovirsen has achieved a 20% functional cure rate in Phase III trials for chronic hepatitis B (CHB) patients, significantly surpassing the 1-3% rate seen with st... -
Ionis ASO Therapy Zanvastro Receives First-Ever FDA Approval for Alexander Disease, Demonstrates Significant Stabilization of Walking Speed
Ionis Pharmaceuticals USA Overview Ionis Pharmaceuticals' antisense oligonucleotide (ASO) therapeutic, Zanvastro (zilganersen), has secured FDA approval as the first treatment for Alexander disease (AxD), a rare and progressive neurodege... -
Gamgee Leverages ChatGPT and AlphaFold to Design Personalized mRNA Cancer Vaccine for Dogs, Accelerating Clinical Trials with AI
Gies Business (Facebook) USA Overview AI is proving to be a catalyst for accelerating all facets of clinical trials, exemplified by Gamgee's use of ChatGPT and AlphaFold to design a personalized mRNA cancer vaccine for dogs, now in clini... -
Superluminal Medicines Secures $60M for AI-Driven Rare Obesity Drug, Clinical Trials Expected This Year
BioPharma Dive USA Overview AI drug discovery startup Superluminal Medicines has raised $60 million to advance its rare obesity therapeutic towards clinical trials. The company's lead candidate targets the G protein-coupled receptor (GPC... -
Insilico Medicine’s AI-Designed Drug Rentosertib Shows Early Signs of Biological Age Reversal, Enters Phase III for Idiopathic Pulmonary Fibrosis
Inc.com USA Overview Insilico Medicine's AI-generated small molecule, rentosertib, has demonstrated early signs of reducing six protein-based biological age markers by an average of 10.3% in a 12-week clinical trial. This breakthrough ma... -
Next-Gen Diagnostics: Single-Cell Analysis, Microfluidics, Biosensors, and AI Converge for Faster, More Precise Detection
Industry Overview International Overview A recent industry overview highlights how the integration of single-cell analysis, microfluidics, biosensors, and artificial intelligence (AI) is revolutionizing diagnostic capabilities. These inn... -
Mayo Clinic and NaNotics Demonstrate NaNots Nanoparticles Restore Anti-Tumor Immunity and Significantly Delay Tumor Growth in Triple-Negative Breast Cancer
Business Wire USA Overview A peer-reviewed study by Mayo Clinic and NaNotics LLC demonstrated a novel nanotechnology approach in cancer immunotherapy using "NaNots" nanoparticles. These engineered adsorptive nanoparticles selectively dep... -
Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers
News-Medical UK Overview Researchers have discovered that the mechanism by which cancer-driving proteins accumulate within tumors significantly influences the efficacy of PROTAC drugs. The study demonstrated that PROTACs are more effecti... -
The Multispecific Antibody Revolution: Reshaping CDMOs for Next-Gen Biologics
BioSpace USA Overview The rapid advancement of multispecific antibody therapeutics is fundamentally transforming the service delivery models and development architectures of Contract Development and Manufacturing Organizations (CDMOs). T...
